Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2005, p. 3483-3485, Vol. 49, No. 8
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.8.3483-3485.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Cambridge, Massachusetts,1 Memorial Sloan-Kettering Cancer Center, New York, New York,2 Takeda Pharmaceutical Company, Ltd., Osaka, Japan,3 Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada4
Received 22 December 2004/ Returned for modification 8 March 2005/ Accepted 25 April 2005
TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»